From major journals, first or last author from the Institute for Cancer Research
Juzeniene A, Stenberg VY, Bruland ØS, Revheim ME, Larsen RH(2023) Dual targeting with 224Ra/212Pb-conjugates for targeted alpha therapy of disseminated cancers: A conceptual approach Front Med (Lausanne), 9, 1051825 DOI 10.3389/fmed.2022.1051825, PubMed 36733936
Kvalvaag A, Valvo S, Céspedes PF, Saliba DG, Kurz E, Korobchevskaya K, Dustin ML(2023) Clathrin mediates both internalization and vesicular release of triggered T cell receptor at the immunological synapse Proc Natl Acad Sci U S A, 120(6), e2211368120 DOI 10.1073/pnas.2211368120, PubMed 36730202
Pulido R, Nunes-Xavier CE(2023) Editorial: Cell and Developmental Signalling in Neuroblastoma Front Cell Dev Biol, 10, 1126352 DOI 10.3389/fcell.2022.1126352, PubMed 36684434
Kvalvaag A, Valvo S, Céspedes PF, Saliba DG, Kurz E, Korobchevskaya K, Dustin ML(2023) Clathrin mediates both internalization and vesicular release of triggered T cell receptor at the immunological synapse Proc Natl Acad Sci U S A, 120(6), e2211368120 DOI 10.1073/pnas.2211368120, PubMed 36730202
Odabasi E, Conkar D, Deretic J, Batman U, Frikstad KM, Patzke S, Firat-Karalar EN(2023) CCDC66 regulates primary cilium length and signaling via interactions with transition zone and axonemal proteins J Cell Sci, 136(3) DOI 10.1242/jcs.260327, PubMed 36606424
Normann LS, Haugen MH, Hongisto V, Aure MR, Leivonen SK, Kristensen VN, Tahiri A, Engebraaten O, Sahlberg KK, Mælandsmo GM(2023) High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer PLoS One, 18(1), e0280507 DOI 10.1371/journal.pone.0280507, PubMed 36706086
